Presentation for Impact of Russia/Ukraine War on Asian Markets-Tiantan Biological Products(600161CH)
333 Views24 Mar 2022 17:16
We analyzed the investment opportunity (Tiantan Biological Products) that is good to consider during both war and pandemic time,covering investment logic, industry characteristics, core moat and risks
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Guanze Intelligent Medical Information Industry - Advantages in Shandong Cannot Hide Worries01 Apr 2022
- Hutchmed China Ltd (13.HK/HCM.US) - Big but Not Strong29 Mar 2022
- China Healthcare Weekly (Mar.25)- Viable Business Model for Pharma, CXO for CGT, China Sleep Economy27 Mar 2022
- Presentation for Impact of Russia/Ukraine War on Asian Markets-Tiantan Biological Products(600161CH)24 Mar 2022
- Russia-Ukraine War: The Impact on China Healthcare09 Mar 2022
- Presentation for Webinar: China Healthcare - Outlook and Opportunities in 202217 Feb 2022
- China Healthcare Weekly (Jan.21)-Growth Hormone VBP,Biotech Survival,Internationalization Conditions23 Jan 2022
x